Business
BioCardia Announces European Patent Office Decision to Grant Patent on Autologous Cell Therapy Patient Selection Diagnostic Assay
SAN CARLOS, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the
About this update from Biocardia, Inc.
[{"type":"text","content":"SAN CARLOS, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the European patent office has issued a Decision to Grant European Patent No. 3593810 to BioCardia with publication on June 23, 2021. The patent broadly describes autologous cell therapy patient selection diagnostics as a solution for the problem of therapeutic variability of different patients’ cells. The patent describes using such an assay approach for patient selection as well as for setting dosage levels for autologous cell-based therapies. Specific patent claims are focused on BioCardia’s lead CardiAMP programs for bone marrow cells for transplantation to the heart intended to treat heart failure and chronic myocardial ischemia. This new patent is anticipated to strengthen the protection of BioCardia efforts with respect to its patient screening methods already afforded by issued patents. “Selecting patients based on the characteristics of their own cells for a therapy created from their own cells is how we are bringing personalized medicine to cell therapy for the treatment of heart disease,” said Dr. Peter Altman, BioCardia CEO. “This new patent protection is expected to enhance our ability to advance the CardiAMP Cell therapy for heart failure and chronic myocardial ischemia in Europe – where our CardiAMP cell processing platform technology and our Helix biotherapeutic delivery offerings have already received approvals.” He continued, “It is unusual in the diagnostic space to have fundamental intellectual property for an entirely new application of existing and known biological markers, let alone a clinical application that also resonates with everyone’s common sense and addresses such an enormous unmet clinical need. We continue to study assay performance with respect to sensitivity, specificity, precision, and agreement for each biomarker as well as the overarching diagnostic algorithm in three laboratories today.” BioCardia believes that with success of the ongoing clinical trial of the CardiAMP cell therapy in ischemic heart failure, this patented and proprietary CardiAMP cell potency biomarker panel assay could be applicable to 1.7 million patients having heart failure in the United States a...